SEC
DXCM icon

Seven Eight Capital’s DexCom DXCM Stock Holding History

Seven Eight Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-117,272
Closed -$7.86M – 184
2024
Q3 		$7.86M Buy
117,272
+70,047
+148% +$5.75M 0.71% 4
2024
Q2 		$5.35M Buy
47,225
+42,123
+826% +$5.33M 0.56% 18
2024
Q1 		$708K Sell
5,102
-828
-14% -$104K 0.07% 384
2023
Q4 		$736K Sell
5,930
-18,204
-75% -$1.86M 0.09% 335
2023
Q3 		$2.25M Buy
24,134
+1,150
+5% +$130K 0.26% 97
2023
Q2 		$2.95M Buy
22,984
+7,530
+49% +$911K 0.49% 50
2023
Q1 		$1.8M Buy
15,454
+12,324
+394% +$1.38M 0.37% 67
2022
Q4 		$354K Sell
3,130
-1,335
-30% -$147K 0.09% 279
2022
Q3 		$360K Buy
4,465
+1,476
+49% +$125K 0.07% 340
2022
Q2 		$223K Buy
+2,989
New +$273K 0.09% 315
2020
Q2 		– Sell
-11,600
Closed -$781K – 393
2020
Q1 		$781K Sell
11,600
-60,872
-84% -$3.79M 0.2% 151
2019
Q4 		$3.96M Buy
+72,472
New +$3.44M 0.21% 147
2019
Q2 		– Sell
-71,672
Closed -$2.13M – 622
2019
Q1 		$2.13M Buy
71,672
+45,820
+177% +$1.61M 0.11% 234
2018
Q4 		$774K Sell
25,852
-190,400
-88% -$6.04M 0.04% 379
2018
Q3 		$7.73M Sell
216,252
-42,800
-17% -$1.33M 0.47% 53
2018
Q2 		$6.15M Buy
259,052
+178,000
+220% +$3.77M 0.43% 77
2018
Q1 		$1.5M Buy
+81,052
New +$1.2M 0.12% 202
2017
Q1 		– Sell
-52,800
Closed -$788K – 555
2016
Q4 		$788K Buy
+52,800
New +$935K 0.16% 222
2016
Q1 		– Sell
-400
Closed -$8K – 578
2015
Q4 		$8K Buy
+400
New +$8.32K 0.01% 516
2015
Q2 		– Sell
-4,400
Closed -$69K – 558
2015
Q1 		$69K Buy
+4,400
New +$66.5K 0.12% 250

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Seven Eight Capital's DXCM Position: Q4 2024 in Review

Seven Eight Capital sold out of DexCom (DXCM) in Q4 2024, closing a stake of 117,272 shares — an estimated $7.86M sold.

Seven Eight Capital first reported a position in DXCM in Q1 2015 and held it in 20 quarters. The position peaked at $7.86M in Q3 2024. 951 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

  • Seven Eight Capital reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 117,272 DexCom shares in Q4 2024, an estimated $7.86M.
  • Seven Eight Capital first reported a position in DexCom in Q1 2015 and held it in 20 quarters.
  • Seven Eight Capital's DexCom position peaked at $7.86M in Q3 2024.
  • 951 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.